Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai grows quantitative brain imaging operations in Europe

(San Diego, CA) May 26, 2016 – Cortechs.ai, the leading medical software innovator providing trusted solutions for quantitative brain analysis, is pleased to announce the acceleration of its international expansion to the European market to address the growing demand for quantitative imaging solutions and to support its existing customer base in Europe.

Cortechs.ai’ flagship solution, NeuroQuant®, received CE mark clearance in 2014, paving the way for many European customers to use Cortechs.ai’ fully automated quantitative brain imaging solutions in clinical practice. Cortechs.ai’ quantitative imaging solutions, NeuroQuant and PETQuant™ provide neurologists, radiologists, and clinical researchers with accurate and convenient tools to quantify the volumes of specific brain structures providing evidenced-based assessments of brain atrophy which could be caused by neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

In conjunction with the expansion into Europe, Cortechs.ai has hired Peter Segers, MSc, to head the European team. Mr. Segers joins the company with over 18 years of market and business development experience in medical devices, with senior roles at Lightpoint Medical, Nucletron and BMEYE, as well as, Philips Medical Systems. He brings a wealth of expertise in building global enterprise relationships and has an extensive knowledge of medical imaging market. Mr. Segers is based out of Amsterdam.

“Our international expansion is a critical step in providing continuing access and support of Cortechs.ai’ proven and reliable quantitative volumetric analysis solutions,” said Guri Stark, CEO of Cortechs.ai. “NeuroQuant has experienced impressive acceptance and success in prominent clinical institutions in the US and we are excited to see the demand and growth in Europe as we expand our solutions and launch our new Multiple Sclerosis products later this summer.”

For more information about Cortechs.ai brain imaging analysis solutions, please visit Stand D40 at the 2nd Congress of the European Academy of Neurology (EAN) taking place May 28-31 in Copenhagen.

PETQuant is available for research use only.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis solutions provide neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

 

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

03/31/2025

How NeuroAlign CT Subtraction Maps Enhance Detection and Confidence in Neuroradiology

What if head CT assessment could be even faster and more accurate? Subtraction maps allow for improved detection and visualization of subtle interval changes.

03/27/2025

Cortechs.ai Joins Forces with Kryptonite Solutions as a Distribution Partner to Expand AI-Driven Neuroimaging Access in India

We are pleased to announce a strategic partnership with Kryptonite Solutions to distribute our innovative portfolio across India.

03/20/2025

Cortechs.ai Announces Strategic Distribution Partnership with Medical Horizons to Expand Presence in Italy, Turkey, and the Middle East

We are pleased to announce a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy.

03/18/2025

Unlocking the Power of AI Imaging in Multiple Sclerosis: How NeuroQuant® MS Enhances Lesion Detection and Monitoring

Unlock the power of AI-driven imaging with NeuroQuant® MS—enhancing lesion detection, monitoring, and personalized care for Multiple Sclerosis.

03/09/2025

Advancing TBI Evaluation with AI-Driven MRI Analysis: A New Era in Brain Health

AI-driven MRI with NeuroQuant® enhances TBI assessment, tracks recovery, and supports better treatment decisions.

03/06/2025

Case Study: Leveraging NeuroQuant® for Accurate Diagnosis of Traumatic Brain Injury

This case highlights the power of advanced neuroimaging tools in delivering precise, evidence-based diagnostics to enhance patient care and clinical decisions.
Scroll to Top